Právní předpis byl sestaven k datu 29.06.2026.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX VLÁDY
ze xxx 11. xxxxxxxx 2024,
kterým xx mění xxxxxxxx xxxxx č. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx xxxxx pozdějších xxxxxxxx
&xxxx;
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 a 2 zákona x. 167/1998 Xx., x xxxxxxxxxx látkách x x xxxxx xxxxxxxxx xxxxxxx zákonů, xx xxxxx xxxxxx x. 273/2013 Sb. a xxxxxx x. 366/2021 Xx.:
Xx. I
Nařízení xxxxx x. 463/2013 Sb., x seznamech xxxxxxxxxx xxxxx, xx znění xxxxxxxx xxxxx x. 243/2015 Xx., xxxxxxxx xxxxx x. 46/2017 Xx., xxxxxxxx vlády x. 30/2018 Xx., xxxxxxxx xxxxx č. 242/2018 Sb., xxxxxxxx xxxxx x. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Xx., xxxxxxxx xxxxx č. 228/2023 Sb., xxxxxxxx xxxxx č. 52/2024 Xx. a nařízení xxxxx x. 176/2024 Xx., se xxxx xxxxx:
1. X xxxxxxx xxxxxxx x. 1 xx xxx řádek, xx xxxxxx xx xx xxxxxxx s xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx jazyce“ xxxxxxx xxxxx „Xxxxxxxx“, vkládá xxxx řádek, ve xxxxxx xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx nechráněný xxxxx (XXX) v xxxxxx xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxx“, xx xxxxxxx x xxxxxx „Chemický xxxxx xxxxx IUPAC“ xx xxxxxxx xxxxx „xxxxxx 4-(X-(2-xxxxxxxxxxxxx)xxxxxx)-1-(2-xxxxxxx-2-xxxxxxx)xxxxxxxxx-4-xxxxxxxxxx“ a xx sloupci x xxxxxx „Xxxxxxxx“ jsou xxxxxxx slova „A-3080, Xxxxxxx“.
2. Příloha x. 3 xxx:
„Xxxxxxx č. 3
Xxxxxx x. 3 xxxxxxxx látek
|
Mezinárodní xxxxxxxxxx xxxxx (XXX) x&xxxx;xxxxxx xxxxxx / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx nebo xxxxx xxxxxx xxxxx |
Xxxxxxxx xxxxx xxxxx IUPAC |
Poznámka |
|
Acetylbenzylfentanyl |
benzylacetylfentanyl |
N-fenyl-N-(1-benzyl-piperidin-4-yl)-acetamid |
NSC 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- xxxxxxxxxxxxxxxxxx; |
1-[4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
XX-238 |
1-[2,6-xxxxxxxx-4-(3-xxxxxxxxx-2-xxxx)xxxxxxxxx-1-xx]xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX-X; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; U 47931X |
4-xxxx-X-(2-(xxxxxxxxxxxxx) xxxxxxxxxx) benzamid |
|
|
Brorfin |
Brorphine |
3-{1-[1-(4-bromfenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-on |
|
|
Butonitazen |
2-[(4-butoxyfenyl)methyl]-N,N-diethyl-5-nitro-lA-benzimidazol-1-ethanamin |
||
|
4-Chlorisobutyrfentanyl |
4-Cl-iBF |
N-(4-chlorfenyl)-2-methyl-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
|
|
Cyklopentylfentanyl |
cyclopentyl-F; XX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
X530 |
4-(4-xxxxxxxxxx)-2,2-xxxxxxx-1-(1-xxxxxxxxxxxx)-1-xxxxxxx |
|
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxxxxxx-2-xxxxx xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx xxxxxxxx |
X-(4-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxx-1-xx)xxxxxx-3-xx |
||
|
Xxxxxx |
xxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]-X,X-xxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
2-{2-[(2,3-xxxxxxx-1-xxxxxxxxxx-5-xx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}-X,X- xxxxxxxxxxxx-1-xxxx |
||
|
Xxxxxxxxxx |
5-xxxxxx xxxxxxxxxxxxx; 5-xxxxxx xxxxxxxxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxxx-1X-xxxxxxxxxxxx-1-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
|
|
Xxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-1-(2-xxxxxxxxxx-1-xxxxxxx)-1X-xxxxxxxxxxxxx |
||
|
Xxxxxxx |
(5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-6,14-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxx butanamid xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Xxxxxxxxxxxxxxxxxxxxx |
β'-xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-x]-3-xxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
X,X-xxxxxxx-2-{2-[(4-xxxxxxxxxx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}xxxxxxxxx |
||
|
2’-Xxxxx-2-xxxxx-3-xxxxxxxxxxxxxx |
X-(1-(2-xxxxxxxxxxxxx)-3-xxxxxxxxxxxxxxx-4-xx)-X-(2-xxxxxxxxxx)xxxxxxxxxxx |
||
|
4-Xxxxx-xxxxxxxxxxxxx |
4X-XX |
X-(4-xxxxxxxxxx)-X-[(1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx)]xxxxxxxxx |
|
|
4-Xxxxx-xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxx-4-xx)-xxxxxxxxxxxxxxxxxxxxx |
|
|
2-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
2-XX, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4F-furanylfentanyl |
N-(4-fluorfenyl)-N-(1-fenethylpiperidin-4-yl)furan-2-karboxamid |
|
|
4-Fluorisobutyrfentanyl |
4F-1BF |
N-(4-fluorfenyl)-2-methyl-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
|
|
3-FluormethoxyacetyIfentanyl |
ortho-fluormethoxyacetyl- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx XX-17 |
X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxx-xxxxx-2-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
XX-X; 2-furanoylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]-furan-2-karboxamid |
|
|
(iso)Butyryl-F-fentanyl X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; p-hydroxybutyryl xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx xxxx |
||
|
Xxxxxxxx-xxxxxxxx |
(4-xxxxxxxxx)-(1-(xxxxxxxxxxxxx)-4-xxxxxxx-4-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxx |
1-[4-(3-xxxxxxx xxxxx)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X xxxxxxxx xxxxxx xxx léčebné xxxxxxx xxxxxxx v xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; MDU-47; MDU-47700 |
N-(2-(dimethylamino)cyklohexyl)-N-methylbenzo[d][1,3]dioxol-5-karboxamid |
|
|
α-Methylfentanyl xxxxxxxxx xxxxxx |
XX; B-F |
2-methyl-N-fenyl-N-[1-(1-fenylpropan-2-yl)piperidin-4-yl]propanamid |
|
|
3 -XxxxxXxxxxxxxXxxxxxxxx |
β'-xxxxxXxxxxxxxXxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-3-xxxxxxxxx-2-xxxxxx |
|
|
Xxxxxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]-5-xxxxxxxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]-X-xxxxx-xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-2-[2-[(4-xxxxxxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
X-xxxxxx X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx xxxxxx |
||
|
XXxxxxxxxx |
X-3217 |
X-(2-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxx, XXX, 127X49 |
1-(4,4-xx(xxxxxxx-2-xx)xxx-3-xx-2-xx)xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-5-xxxxx-2-[(4-xxxxxxxxxxxx)xxxxxx]-1-X-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxx |
5-xxxxx-2-[(4-xxxxxxxxxxxxx)xxxxxx]-1-(2-xxxxxxxxxx-1-xxxxxxx)xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxx |
2-xxxxxxxxxxx fentanyl |
N-(1-fenethylpiperidin-4-yl)-N-fenylthiofen-2-karboxamid |
|
|
4-(Trifluormethyl) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] benzenacetamid |
||
|
U-51754 |
2-(3,4-dichlorfenyl)-N-[2-(dimethylamino)cyklohexyl]-N-methylacetamid |
||
|
ValeryIfentanyl |
TCE, XX |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxx]xxxxxxxxxx; xxxxxxxx pentanamid analog |
Včetně xxxx omamných xxxxx xxxxxxxxx v xxxx xxxxxxx xx xxxxx xxxxxxxxx, xxx tyto xxxx xxxxx xxxxxxxxx.“.
3. X xxxxxxx přílohy x. 6 se xxx xxxxx, xx xxxxxx xx ve xxxxxxx x názvem „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxxx“, vkládá nový xxxxx, ve kterém xx ve xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx název (XXX) x českém jazyce“ xxxxxxx slovo „Xxxxxxxxxxxxxxxx“, xx sloupci s xxxxxx „Xxxxx xxxxxxxxxxx xxxxxxxxxx název xxxx xxxxx obecný xxxxx“ xx xxxxxx text „XXX“, xx sloupci x xxxxxx „Xxxxxxxx xxxxx podle XXXXX“ xx xxxxxxx slovo „xxxxxx-2-xx“ x ve xxxxxxx s xxxxxx „Xxxxxxxx“ je uvedeno xxxxx „gamma-butyrolactone“.
Čl. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx bylo xxxxxxxx x souladu se xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) 2015/1535 ze dne 9. xxxx 2015 x xxxxxxx xxx xxxxxxxxxxx informací v xxxxxxx technických xxxxxxxx x xxxxxxxx pro xxxxxx informační xxxxxxxxxxx.
Čl. XXX
Xxxxxxxx
Xxxx xxxxxxxx xxxxxx xxxxxxxxx xxxx 1. xxxxx 2025, x xxxxxxxx xxxxxxxxxx čl. I bodu 3, xxxxx xxxxxx xxxxxxxxx xxxx 1. xxxxx 2025.
&xxxx;
Xxxxxxxx vlády:
prof. XxXx. Xxxxx, Ph.D., LL.M., x. x.
&xxxx;
Xxxxxxxxxxxxx xxxxx x ministr xxxxxxxxxxxxx:
xxxx. XXXx. Xxxxx, CSc., XXX, XXXX, x. x.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 419/2024 Xx. xxxxx xxxxxxxxx xxxx 1.1.2025, x xxxxxxxx xxxxxxxxxx čl. I xxxx 3, xxxxx xxxxxx účinnosti 1.4.2025.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx právního xxxxxxxx.